Description

FERINJECT 500 MG INJ 10ML

Indications

FERINJECT 500 MG INJ 10ML, containing ferric carboxymaltose, is indicated for the treatment of iron deficiency anemia in adults. It is particularly beneficial for patients who have insufficient oral iron intake, those who have experienced intolerance to oral iron supplements, or individuals who have increased iron requirements due to conditions such as pregnancy, chronic kidney disease, or inflammatory bowel disease. Additionally, FERINJECT is used in patients who require rapid replenishment of iron stores.

Mechanism of Action

FERINJECT functions as a parenteral iron replacement therapy. The active ingredient, ferric carboxymaltose, is a complex of iron and a carbohydrate that allows for the controlled release of iron into the bloodstream. Once administered, it is taken up by transferrin, a plasma protein that transports iron to various tissues, including the bone marrow, where it is utilized for hemoglobin synthesis. This mechanism effectively replenishes iron stores and corrects iron deficiency anemia.

Pharmacological Properties

FERINJECT exhibits a unique pharmacokinetic profile characterized by its rapid absorption and distribution. After intravenous administration, ferric carboxymaltose is rapidly distributed in the bloodstream, with a bioavailability approaching 100%. The half-life of the drug is approximately 7 to 10 hours, allowing for once or twice weekly dosing depending on the severity of the deficiency. The drug is primarily eliminated through the reticuloendothelial system, with minimal renal excretion, making it suitable for patients with compromised renal function.

Contraindications

FERINJECT is contraindicated in patients with known hypersensitivity to ferric carboxymaltose or any of its components. It should not be used in patients with iron overload syndromes, such as hemosiderosis or hemochromatosis, as excessive iron can lead to serious complications. Additionally, it is contraindicated in patients with severe liver dysfunction, where iron metabolism may be impaired.

Side Effects

The administration of FERINJECT may be associated with various side effects. Commonly reported adverse reactions include headache, dizziness, and gastrointestinal disturbances such as nausea and diarrhea. Local reactions at the injection site, including pain, swelling, and redness, may also occur. Rare but serious side effects include hypersensitivity reactions, including anaphylaxis, and hypotension. Patients should be monitored for signs of these reactions during and after administration.

Dosage and Administration

FERINJECT is administered intravenously, either as a slow injection or infusion. The recommended dosage for adults is typically 500 mg (10 mL) administered over a period of 15 minutes. In cases of severe iron deficiency anemia, a second dose may be given after a minimum of 7 days. The total cumulative dose should not exceed 1000 mg within a single course of treatment. It is essential to assess the patient’s hemoglobin levels and iron stores regularly to determine the need for additional doses.

Interactions

FERINJECT may interact with certain medications and substances. The concurrent use of other iron preparations, either oral or parenteral, should be avoided to prevent iron overload. Additionally, medications that affect iron absorption, such as antacids or proton pump inhibitors, may reduce the efficacy of oral iron supplements but are generally not a concern with intravenous administration of FERINJECT. It is advisable to inform healthcare providers of all medications being taken to avoid potential interactions.

Precautions

Before administering FERINJECT, a thorough medical history should be obtained to identify any pre-existing conditions that may contraindicate its use. Special caution should be exercised in patients with a history of asthma, eczema, or allergic reactions, as they may be at higher risk for hypersensitivity reactions. Monitoring of iron levels and hemoglobin should be conducted to ensure appropriate dosing and to avoid iron overload. In patients with renal impairment, dosage adjustments may be necessary, and close monitoring is recommended.

Clinical Studies

Clinical studies have demonstrated the efficacy and safety of FERINJECT in treating iron deficiency anemia. In a randomized controlled trial involving patients with chronic kidney disease, those receiving FERINJECT showed significant improvements in hemoglobin levels compared to those receiving placebo. Another study highlighted the rapid increase in iron stores and hemoglobin levels in patients with inflammatory bowel disease after administration of FERINJECT. These studies support the use of FERINJECT as a safe and effective option for managing iron deficiency anemia in various patient populations.

Conclusion

FERINJECT 500 MG INJ 10ML is a valuable therapeutic option for the treatment of iron deficiency anemia, particularly in patients who cannot tolerate oral iron or require rapid iron replenishment. Its unique formulation allows for effective iron delivery with a favorable safety profile. However, careful consideration of contraindications, potential side effects, and patient-specific factors is essential to ensure optimal outcomes. Ongoing monitoring and assessment of iron levels are crucial to the successful management of iron deficiency anemia with FERINJECT.